Navigation Links
Access and Somanta Announce Data to be Presented on Angiolix at,ASCO Oncology Conference

Pre-clinical Data Suggests Angiolix Can Inhibit Breast Cancer Growth By 75%

DALLAS and IRVINE, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (Bulletin Board: ACCP) and Somanta Pharmaceuticals, Inc. (Bulletin Board: SMPM) announced today that a scientific abstract outlining new preclinical efficacy data for Somanta's Angiolix has been selected for publication in the Proceedings of the 43rd American Society of Clinical Oncology (ASCO) Annual Meeting to be held in Chicago, IL, June 1-5, 2007. The data, in a study conducted using mouse models, shows that Angiolix has been able to achieve more than 75% growth inhibition of human breast cancer growing as xenografts in mouse.

ASCO's annual meeting is the world's premier oncology conference providing information on the latest developments in cancer treatment. As previously announced Access and Somanta have signed a definitive merger agreement for Access to acquire Somanta as a step in the creation of a combined company with a broad cancer-focused portfolio in which Angiolix will be a major program.

Angiolix is a humanized monoclonal antibody that recognizes a migrating adhesion molecule called Lactadherin. Somanta's recent data suggests that tumor cells express Lactadherin which is a factor in the growth of tumor vasculature. Several existing or potential anti-cancer drugs (such as Avastin) seek to block tumor vascularization by blocking a signaling protein know as vascular endothelial growth factor (VEGF). The binding of Angiolix to Lactadherin is thought to cause a VEGF-independent integrin receptor signaling cascade that blocks vascular endothelial cell proliferation. Due to its ability to neutralize Lactadherin-integrin receptor binding, Angiolix may be able to specifically target breast cancer cells and thereby cause tumor suppression by blocking the growth of tumor vasculature.

Dr. Agamemnon Epenetos, CEO of Som anta and a coauthor of the Angiolix abstract commented, "We are pleased to be presenting data on Angiolix at this year's ASCO conference. The preclinical data shows exciting results in a widely used model of breast cancer. By targeting tumor vascularization, Angiolix has the potential to cause tumor regression and prevent recurrence of growth."

"On behalf of both companies we are grateful for the opportunity to present data at this year's ASCO Conference," added Stephen R. Seiler, Access' President and CEO. "Recent studies indicate that Angiolix has the potential to choke off blood flow to breast tumors, which inherently causes tumor regression."

About Access

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase II clinical testing of patients with ovarian cancer and MuGard(TM) for the management of patients with mucositis. The Company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery. For additional information on Access Pharmaceuticals, please visit our website at http://www.accesspharma.com .

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties, including statements relating to the efficacy and method of action of Angiolix, the value of our products in the market, our ability to achieve clinical and commercial success, our ability to successfully develop marketed products and the ability to obtain the approvals of Somanta's stockholders, to obtain or meet the closing conditions in the merger agreement, including applicable regulatory and tax requirements, and to otherwise complete the m erger in a timely manner. These statements are subject to numerous risks, including but not limited to the risks detailed in Access' and Somanta's Annual Report on Form 10-KSB and other reports filed by Access and Somanta with the Securities and Exchange Commission.

CONTACT: Company, Stephen B. Thompson, Vice President and Chief FinancialOfficer of Access Pharmaceuticals, Inc., +1-214-905-5100; Investors, DonaldC. Weinberger or Alisa Steinberg of Wolfe Axelrod Weinberger Assoc. LLC,+1-212-370-4500, for Access Pharmaceuticals, Inc.; or Andrew Hellman ofCEOcast, Inc., +1-212-732-4300, for Access Pharmaceuticals, Inc.

Web site: http://www.accesspharma.com/

Ticker Symbol: (:ACCP),(:SMPM)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. PromegaExpress Expands Easy Access to Products with New Cabinet
2. Access Pharmaceuticals Announces Poster Presentations on ProLindac at the American Association for Cancer Research 2007 Annual Meeting
3. Somanta Announces the Presentation of Alchemix Data at The American Association for Cancer Research Annual Meeting
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2017)... , Aug. 3, 2017  Agragen, LLC, a ... active in the biopharmaceutical, nutraceutical, and aquacultural feed ... of its lead drug candidates, AGR131.  This drug ... cytokine from the blood of patients suffering from ... inflammatory bowel disease. ...
(Date:8/2/2017)... CaryRx, a next-generation full-service pharmacy, has announced the ... in the Washington D.C. metropolitan area. ... delivery of medications through the convenience of its patient-friendly mobile ... within one hour to any location in D.C. ... invaluable service to Washington D.C. ," says ...
(Date:7/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: ... quarter ended June 30, 2017, and updated its financial ... For the fiscal third quarter, Hill-Rom reported ... per diluted share in the prior-year period. These results ... per diluted share primarily related to the non-cash write-down ...
Breaking Medicine Technology:
(Date:8/18/2017)... St. Louis, Missouri (PRWEB) , ... August 18, 2017 , ... ... ” says Suzanne Tucker, Founder of St. Louis-based positive education company Generation Mindful. To ... way they help children learn social and emotional skills, she created the Time-In Toolkit, ...
(Date:8/18/2017)... ... ... Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, has released a ... to the mother of the Savior whom the world calls “Mother Mary”. Yisrayl says when ... role of this historical woman. , “The world bows, kisses the feet of, cries ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... Inc. magazine ... list, the most prestigious ranking of the nation's fastest-growing private companies. This marks the ... exclusive Inc. 5000 ranking . This year’s ranking reflects ASH’s 76 percent overall ...
(Date:8/18/2017)... ... ... “Our Mountains to Climb: A Journey of Love and Faith Through Trials”: ... the faith they shared to overcome struggles in life. “Our Mountains to Climb: A ... J. Corcoran, a retired teacher and happily married since 1999; the author’s personal experiences ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... “Three Narrow ... Roads” is the creation of published author, Rev. Dr. Burnett King Sr., is currently ... coach and founder of the Faith Track Club, Inc., a track-and-field program geared towards ...
Breaking Medicine News(10 mins):